Developing a New Class of Drugs Targeting Solute Carrier Proteins

A high-profile founding team and intellectual property from the leading research institutions CeMM and IST Austria

Solgate applies methods from chemistry, cell biology, and advanced analytics to develop drugs that target membrane transporters known as solute carrier proteins (SLCs) – a novel, largely unexploited, and highly promising class of drug targets that show promise in the development of breakthrough treatments for challenging diseases. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs.

The company is located at IST PARK, and is the first start-up born out of a cooperation between CeMM and IST Austria.



Ariel Bensimon
Co-Founder, CEO